A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|HER2-positive Breast Cancer
Interventions: DRUG: Pyrotinib|DRUG: SHR6390|DRUG: Letrozole|DRUG: Capecitabine
Sponsor: Jinming Yu
Collaborators: Jiangsu HengRui Medicine Co., Ltd.